Clinical Update - 4D Announce New Study of MRx0518 in Pancreatic Cancer |
| January 06, 2020 | January 2020 Bond Updates |
|
LEEDS, England, Jan. 6, 2020 /PRNewswire/ -- 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces the opening of a clinical study to evaluate the safety and preliminary clinical efficacy of MRx0518 in combination with... |
| View more at: https://www.prnewswire.com:443/news-releases/clinical-update--4d-announce-new-study-of-mrx0518-in-pancreatic-cancer-300981352.html |
| Related News |
|